Elutia - Class A opened at $0.92, in line with its previous close of $0.92. In the last trading session, the stock traded between $0.86 and $0.94. It showed a downward intraday trend.
An investment of $100 made 4 years ago in Elutia - Class A is now worth
$ 61.12
Resulting in a loss of
$ 38.88 (38.88%)
Note: Past profits do not guarantee future returns.
Rating from 1 Analysts
Today's Change
$-0.05 (-5.43%)
Day High
$0.94
Day Low
$0.86
Day Open
$0.92
Prev Close
$0.92
Volume
80,923
1W Return
14.62%
1M Return
9.85%
3M Return
8.61%
6M Return
-17.92%
1Y Return
5.61%
Market Cap ($ Mn)
39
PE Ratio
-
PB Ratio
2.48
PEG Ratio
-
ROE
-
ROCE
-370.11%
EPS (TTM)
$-0.17
1 Week
14.62%
1 Month
9.85%
3 Months
8.61%
6 Months
-17.92%
9 Months
-3.35%
Elutia Q3FY26 Results: Revenue up 20%, secures $26M non-dilutive funding
Revenue from continuing operations rose 20% YoY to $1.1 million. Secured $26 million in non-dilutive funding via debt and asset sales. NXT41X GLP study met endpoints; FDA submission planned for Q4. Net loss widened to $6.5 million due to increased R&D spending. Cash position stands at $29.1 million, excluding recent $8 million receipt.
7 days agoElutia receives $8 million escrow release from Boston Scientific
Elutia received the full $8 million escrow holdback from Boston Scientific. The payment completes the third and final funding milestone for 2026. Company is now funded through the NXT-41x launch and into 2029. No equity offering is required due to successful capital execution.
1mo agoElutia to present at Lake Street and Wainwright investor conferences
Elutia management to present at Lake Street and H.C. Wainwright conferences in September 2026. CEO Dr. Randy Mills, CFO Matthew Ferguson, and CSO Dr. Michelle Williams to lead investor engagements. Presentations focus on drug-eluting biomatrix technology for post-surgical infection prevention. One-on-one meetings available for institutional investors at both events.
2mo agoElutia Q2 EPS $(0.17) misses estimate, secures $26M capital
Elutia reported Q2 2026 net sales of $2.427 million and a net loss of $(0.17) per share, missing analyst estimates. The company secured up to $26 million in non-equity capital, combining a credit facility and Simpliderm divestiture proceeds, to fund operations through the 2028 commercial launch of NXT-41x. Gross margins expanded to 59.6%, while independent surgeon surveys indicate strong adoption intent for the upcoming product.
3mo agoElutia secures $15 million loan to fund NXT-41x launch
Elutia Inc. secured a $15 million loan from Avenue Capital Group to fund the commercialization of NXT-41x, targeting a $1.5 billion market in plastic and reconstructive surgery. The deal includes a $10 million immediate tranche and a $5 million contingent tranche upon FDA clearance expected in H1 2027, preserving shareholder value by avoiding equity dilution.
3mo agoElutia Q2 Results: Financials due Aug 13, webcast follows
Elutia Inc. will report second quarter 2026 financial results after market close on August 13, 2026. Management will host a conference call at 5:00 p.m. Eastern Time, accessible via webcast and dial-in. Archived coverage will be available on the company's investor relations website.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $109.29 | -1.06% | $1,89,283.94M | 36.28 | |
| $449.53 | -0.11% | $1,55,826.88M | 42.73 | |
| $101.61 | +0.02% | $1,29,976.46M | 24.46 | |
| $318.79 | -1.70% | $1,21,360.48M | 34.27 | |
| $45.13 | +0.96% | $65,414.72M | 18.96 | |
| $105.81 | +1.73% | $60,840.75M | 53.70 | |
| $214.52 | +0.90% | $58,432.46M | 44.07 | |
| $82.60 | -1.26% | $37,346.60M | 16.49 | |
| $42.16 | +3.06% | $37,044.18M | 89.05 | |
| $72.46 | -2.16% | $35,027.16M | 54.55 | |
| $237.20 | +1.61% | $33,458.08M | 23.04 | |
| $80.35 | +0.53% | $29,964.75M | 36.04 |
An investment of $100 made 4 years ago in Elutia - Class A is now worth
$ 61.12
Resulting in a loss of
$ 38.88 (38.88%)
Note: Past profits do not guarantee future returns.
